3Georg A. Bjarnason,Ian G. Kerr,Nancy Doyle,Moira Macdonald,Marcia Sone. Phase I study of 5-fluorouracil and leucovorin by a 14-day circadian infusion in metastatic adenocarcinoma patients[J] 1993,Cancer Chemotherapy and Pharmacology(3):221～228
4Marco Treskes,Wim J. F. Vijgh. WR2721 as a modulator of cisplatin-and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach[J] 1993,Cancer Chemotherapy and Pharmacology(2):93～106
5Barbara A. Conley,Merrill J. Egorin,Victoria Sinibaldi,Gerald Sewack,Curtis Kloc,Lynelle Roberts,Eleanor G. Zuhowski,Alan Forrest,David A. Echo. Approaches to optimal dosing of hexamethylene bisacetamide[J] 1992,Cancer Chemotherapy and Pharmacology(1):37～45
6J. M. A. Gerven,A. Hovestadt,J. W. B. Moll,C. J. Rodenburg,T. A. W. Splinter,A. T. Oosterom,L. Keizer,T. E. Drogendijk,C. M. Groenhout,Ch. J. Vecht,J. P. Neijt. The effects of an ACTH (4–9) analogue on development of cisplatin neuropathy in testicular cancer: A randomized trial[J] 1994,Journal of Neurology(7):432～435
